M5S: i malati sono stati traditi ancora una volta, serve un referendum consultivo sulla cannabis

Dopo il voto di ieri, che ha visto naufragare per una manciata di voti due emendamenti che avrebbero consentito l’autoproduzione di cannabis per i malati, il Movimento 5 Stelle, ha emesso un duro comunicato, nel quale punta il dito contro il Partito Democratico, accusandolo di aver tradito i malati, e preannuncia il tentativo – per la prossima legislatura – di cercare di indire un referendum popolare consultivo sulla legalizzazione. Ecco il testo.

promotore dell’emendamento per l’autoproduzione bocciato ieri dalla Camera

in Cannabis / High times  20 ottobre 2017

“Il Movimento 5 Stelle ha votato favorevole per senso di responsabilità nei confronti dei tanti malati che chiedono un intervento in materia, sperando che il Senato possa approvare questa legge. Siamo contenti che, grazie anche alla nostra insistenza, per la prima volta si sia discusso alla Camera dei Deputati di legalizzazione della cannabis. È solo il primo passo, nella prossima legislatura l’argomento dovrà essere affrontato anche attraverso un referendum popolare consultivo, così che i partiti non potranno più nascondersi e dovranno prendersi le loro responsabilità.

Negare la legalizzazione è stato l’ultimo atto ipocrita del PD, che permette alla criminalità di prosperare. Una scelta ideologica, falsa e dannosa che non vuole vedere quanto sta accadendo a livello internazionale: la legalizzazione sta portando un sostanziale abbassamento dei reati, maggiori entrate fiscali, una diminuzione del consumo soprattutto tra i giovani . Non è bastato al PD quanto affermato dalla Direzione Nazionale Antimafia e Antiterrorismo che i tempi erano maturi per legalizzare, perché la criminalizzazione non ha prodotto nessun effetto, se non quello di aumentare il consumo, le entrate alla mafia ed il contatto dei giovani con il crimine, droghe pesanti e sostanze tossiche.

Anche in Italia potremmo controllare il fenomeno regolamentando un mercato che di fatto è già libero. In questo modo si potrebbero impegnare le forze dell’ordine ed i magistrati sul perseguimento di reati gravi e al contempo destinare una parte di quelle risorse economiche alla giustizia, alla prevenzione dell’utilizzo di droghe, alla sanità. Perché i partiti contrari non hanno fatto proposte contro tabacco e alcool visto che provocano migliaia di morti ogni anno in Italia? Mentre non c’è un morto accertato per uso di cannabis, una vera e propria ipocrisia.

Nulla da fare il PD e la sua strampalata maggioranza hanno eliminato la parte su coltivazione per uso personale e monopolio di Stato sulle vendite, tutto questo lasciando solo la parte terapeutica che il Ministro Lorenzin con un Decreto Ministeriale poteva risolvere senza perdere ulteriore tempo; tempo che manca ai tanti malati che oggi in Italia non riescono ad accedere alle cure a base di cannabis. La cosa più triste è vedere che a distruggere questa legge non sono stati solo i rappresentanti di Lega Nord, FI, e FdI che ideologicamente rigettano anche i dati più evidenti, ma gli stessi deputati del PD che hanno sottoscritto la proposta di legge dell’intergruppo per la legalizzazione: Giachetti e Giuditta Pini in testa, che hanno tradito il lavoro che avevano sostenuto in questi anni”.

 

 

 

 

http://www.dolcevitaonline.it/m5s-i-malati-sono-stati-traditi-ancora-una-volta-serve-un-referendum-consultivo-sulla-cannabis/

Annunci

UNIVERSITY STUDY FINDS THAT MOST PATIENTS BENEFIT FROM MEDICAL MARIJUANA TREATMENT

FIRST RESEARCH INTO LEGAL CANNABIS USAGE REVEALED AT INTERNATIONAL HEALTH CONFERENCE IN JERUSALEM.


The first study on the characteristics of patients with Health Ministry permission for treatment with medical marijuana – until now an unknown field – was revealed on Wednesday at the Sixth International Jerusalem Conference on Health Policy.

The conference was organized by the Israel National Institute for Health Policy Research.

The study was led by Prof. Pesach Shvartzman of Ben-Gurion University of the Negev’s Health Sciences Faculty, who said even though medical cannabis has been legal for a decade and is licensed to more than 20,000 patients for relieving pain and other symptoms, “there has been no information about the users themselves.”

Prof. Pesach Shvartzman

Shvartzman concluded that most users enjoy significant improvement in pain and function, but that the cannabis also caused side effects.

 

The study, carried out to observe new patients using the drug for two years, looked at their socioeconomic characteristics, disease profiles, the medical indication for use, dosages, treatment given to the patient before giving cannabis, treatment safety, side effects, response and effectiveness of treatment and the patient’s use of health services during the year prior to and the year following treatment.

The patients were observed at three pain clinics and were interviewed by phone during the first three months of their treatment and then every four months for two years.

Of 321 non-cancer patients, 47.4 percent were male and the rest female. Of the 78 cancer patients, 60% were male.

The mean age of the non-cancer patients was 50.1 years and of cancer patients 57.5 years.

Of the cancer patients, 47% of the non-cancer and 40% of the cancer patients were native Israelis.

A total of 53.8% of the cancer patients and 56.9 of the cancer patients were secular.

Forty percent of the non-cancer patients and 49.3% of the cancer patients were employed. Of the non-cancer patients, 30.4% and 47.9% of the cancer patients had an academic education. Of the non-cancer patients, 56.7% were married, compared to 65.3% of the cancer patients.

Some 42% of all the patients had received recommendations for medical cannabis from their doctors, while only 24% from a friend or family member.

The prescriptions for the drug were most commonly given by palliative medicine specialists, orthopedists, and other specialists and only a tiny minority (0.4%) from the family physician.

Fully 99.6% applied for marijuana supplies after taking conventional medications that were not effective.

Nearly 56% said they wanted it because the previous drugs caused side effects.

Three-quarters of patients smoked the marijuana, while nearly 21% used concentrations in oil and the rest via vaporization.

More than 77% suffered from side effects; the moist frequent were dry mouth (60.6%); hunger (60%); 44% high moods; 23% sleepiness; 28.6% fatigue; 32% red eyes; and 13% blurred vision.

Most of the users reported in later interviews that their pain, nausea, anxiety, appetite and general feeling had improved. Fewer than one in 10 stopped taking the drug after the first interview and 6% after the second interview because of side effects and because the treatment was not effective.

Meanwhile, the Washington University School of Medicine in St. Louis has just reported on a study of adolescents’ use of non-medical marijuana in the US, which indicated that the number of teens with marijuana-related problems is declining. Similarly, the rates of marijuana use by young people are falling despite the fact more US states are legalizing or decriminalizing marijuana use and the number of adults using the drug has increased.

The researchers examined data on drug use collected from young people aged 12 to 17 over a 12-year span. They found that the number of adolescents who had problems related to marijuana – such as becoming dependent on the drug or having trouble in school and in relationships – declined by 24% from 2002 to 2013.

–Jerusalem Post

 

 

 

https://medicalmarijuana411.com/university-study-finds-medical-marijuana-helps-manage-pain/?utm_source=newsletter101017&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

Cannabis in Italia: 20 milioni di potenziali pazienti

Mettere in condizione una persona malata di poter aver accesso alla propria cura in un Paese civile sarebbe una priorità. E significherebbe consentire a tutti i pazienti, indipendentemente da dove abitino, di poter ricevere il proprio farmaco a carico del servizio sanitario nazionale, trovare un medico che lo prescriva senza far resistenze dettate spesso dalla scarsa conoscenza della materia, e vedersi garantita la continuità di cura. Al di là dei motivi la situazione è questa: migliaia di malati italiani sono abbandonati a loro stessi e l’unica alternativa che il nostro Stato lascia loro è quella di scendere in strada, cercare uno spacciatore, ed acquistare cannabis che nei casi migliori è di pessima qualità e contiene muffe e contaminanti che un malato dovrebbe assolutamente evitare, ed in tutti i casi va ad ingrassare le tasche già gonfie di mafie e criminalità. Per cui oggi abbiamo scelto di dare i numeri.

Le cifre sul numero di pazienti e quantitativi di cannabis che vengono distribuiti in Canada ed Israele, Paesi in cui l’ipocrisia di Stato è stata messa da parte anni fa per concentrarsi sulla salute dei propri cittadini.

 

LA SITUAZIONE ITALIANA (vedi tabella) Partendo dal nostro Paese il numero è questo: i pazienti italiani che potenzialmente potrebbero avere accesso alle cure con la cannabis sono oltre 20 milioni, un terzo della nostra popolazione.
Il numero è stato calcolato dal dottor Giampaolo Grassi incrociando i dati del ministero della Salute, delle associazioni e delle pubblicazioni scientifiche a riguardo, considerando solo le principali patologie per la quale viene dispensata: circa 17 milioni di persone che soffrono di dolore cronico, 2.900.000 affette da tumore, 500mila da diverse forme di epilessia, 100mila affette da colite e morbo di Crohn, 68mila con sclerosi multipla e circa 4mila da Aids.
Non ci sono stime precise su quante persone abbiano avuto accesso alla cannabis terapeutica nel 2016, ma sicuramente siamo ben lontani da queste realtà. Abbiamo provato più volte a scrivere al ministero della Salute per avere informazioni a riguardo, ma fino ad oggi non abbiamo avuto risposta. Nel migliore dei casi si tratta di poche migliaia. Mentre i dati della cannabis importata dall’Olanda dicono che nel 2016 ne sono stati distribuiti 350 chilogrammi, ai quali vanno aggiunti circa 30 chilogrammi di cannabis prodotta in Italia. Il totale fa circa 380 chilogrammi di cannabis distribuita ai pazienti, tanta quanta nel piccolo Israele ne è stata dispensata in un mese.

 


ISRAELE E CANNABIS. Israele infatti è uno dei Paesi più avanti dal punto di vista della cannabis e del suo studio scientifico. Il governo ha da poco stanziato 20 milioni di euro per la ricerca scientifica sulla cannabis e per innovare genetiche e metodi produttivi. Israele con i suoi 8 milioni di abitanti, nel 2016 contava oltre 22mila pazienti che oggi sono 30mila, grazie anche alle recenti politiche governative che hanno facilitato l’accesso al farmaco; nel 2016 ne sono stati dispensati circa 400 chili al mese per un totale di circa 5 tonnellate.


L’ESEMPIO CANADESE. In Canada la cannabis è stata resa legale per uso medico nel 2001. Attualmente il sistema funziona con i produttori che chiedono la licenza statale, ed i pazienti che, dopo la registrazione, possono o recarsi nei dispensari ad acquistare la cannabis, oppure farsi consigliare le genetiche più appropriate per la propria patologia per poi coltivare in autonomia. Nel caso in cui la patologia del paziente sia debilitante a tal punto da non permettergli di coltivare, può nominare una persona a sua scelta che lo faccia al posto suo.

In Canada, dove vivono 35 milioni di persone a fronte dei nostri 60 milioni, dai 30mila pazienti registrati nel 2015, si è passati ai 100mila del 2016, per arrivare agli attuali 130mila. Nel 2014 erano 8mila. Per i bisogni di questi pazienti nel 2016 sono state distribuite quasi 9 tonnellate di cannabis, proveniente dai 130 produttori autorizzati, senza dimenticare quella che i pazienti si autocoltivano.

 

 

 

http://www.dolcevitaonline.it/cannabis-in-italia-20-milioni-di-potenziali-pazienti/

 

MICHELLE SEXTON, NATUROPATHIC DOCTOR, DISCUSSES CANNABIS AS A MEDICINE PLANT

Dr. Michelle Sexton, a naturopathic doctor based in Seattle, Washington, has been studying plant medicine for over three decades, and has recently opened a laboratory where her research and testing will take the industry to new heights.

You can learn more about her lab by visiting her website, Phytalytics.org.

 

 

https://medicalmarijuana411.com/michelle-sexton-naturalpathic-doctor-discusses-cannabis-as-a-medicine-plant/?utm_source=newsletter100517&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

DA GREEN CORNER GROW-SHOP A FAENZA (RA), I PREZZI PIU’ ECONOMICI SU TUTTA LA VASTA GAMMA DI PRODOTTI TERAPEUTICI A BASE DI CANAPA SATIVA INDUSTRIALE!! ALTRO CHE’ EASY JOINT!!

stiamo ovviamente parlando di canapa a bassissimo tenore di #thc (la molecola psicotropa-terapeutica) e quindi in libera vendita, presso rivenditori e negozi specializzati nella vendita di prodotti a base appunto di canapa, e senza l’obbligo della ricetta medica!!
come specificato all’infinito ormai in moltissimi post che ho dedicato all’argomento, le varieta’ sativa di cannabis industriale (o canapa che dir si voglia), mantengono ottime sostanze terapeutiche fra le quali, in primis i #cbd, i #terpeni e le #antocianidine.
tutte le sostanze elencate svolgono azioni :

– #antinfiammatoria (anti COX-1 e COX-2)
– #antitumorale (antiangiogenetica, apoptotica, antiproliferativa, antimetastatica)
– #antinfiammatoria (anti COX-1 e COX-2)
– #antitumorale (antiangiogenetica, apoptotica, antiproliferativa, antimetastatica)
– #antiossidante
– #antibiotica
– #antivirale
– #antibatterica
– #antimicotica
– #sedativa
– #tonica
– #immunomodulante
– #antidolorifica – #analgesica (azione rivolta sia al dolore neuropatico che nocicettivo)
– #antidepressiva

TISANE ED INFUSI MISTI ALLA CANAPA:

– THE’ NATURALE ANTINFIAMMATORIO con canapa + timo + rosmarino + origano + echinacea. questa e’ un ottima tisana terapeutica che esplica le seguenti azioni: sedativa, battericida, antifungina, digestiva, antielmintica, immunistimolante, anticancro, antiossidante, antinfiammatoria! e’ particolarmente indicata per rinforzare le difese e difender l’organismo dall’attacco di batteri gram-positivi tipici della stagione fredda e che colpiscono le vie aeree!
THE’ RELAX SEDATIVO con canapa + melissa + camomilla + fiori d’arancio. tisana studiata per conciliare il sonno, alleviare la tensione e la depressione.
THE’ ANTIVIRALE-ANTINFIAMMATORIO canapa + liquerizia. perfetto abbinamento di due fitoterapici apparentemente opposti, la canapa e’ principalmente androgenica mentre la liquerizia e’ estrogenica, ma che svolgono molte azioni in sinergia. sia la canapa che la liquerizia sono antidolorifiche-antitumorali e antivirali (la liquerizia cura epatiti b e c stimolando la produzione di interferone, il piu’ potente ormone dall’azione antivirale). l’azione leggermente ipertensiva della liquerizia viene contrastata da quella di alcuni terpeni della cannabis.

PATIENT STORY – DAUGHTER STARTS MEDICAL MARIJUANA COLLECTIVE AFTER MOTHERS PASSING

PATIENT STORY- MYRIAM PEÑA

MYRIAM PEÑA

 

Daughter Starts Medical Marijuana Collective After Mothers Passing- Diana Peña became an advocate for medical marijuana after her mother had a better quality of life, she outlived life expectancy expectations by over a year, with a better quality of life.

 

 

 

FROM DIANA PEÑA
On January 14, 2013 our mother, Myriam, was diagnosed with Stage IV Glioblastoma brain cancer, one of the most aggressive forms of brain cancer.

It was a devastating diagnosis to say the least, but in the midst of desperation came determination and hope. We had been encouraged by mom’s holistic doctor to seek out information on Cannabis Oil, so we searched and discovered information on how to make and dose Cannabis Oil ourselves. From the moment we got her started on the Cannabis Oil, our mom immediately started getting better; MRI’s have all shown tumor shrinkage, blood count test have all come back with favorable results, etc. We became very involved in Social Media during the healing journey and sharing our mom’s story has brought us to connect with many other patients with not only brain cancer but other cancers and ailments which can only be treated with costly pharmaceuticals that can cause sever side-effects or with Cannabis.

MEDICAL MARIJUANA AND HOSPICE TREATMENT

Doctors had given Myriam a prognosis of three months to live, and there was “not a whole lot they could do” except extend her life a bit. With cannabis oil as a staple in her mom’s treatment plan, Peña said her mom outlived expectations by over a year, with a better quality of life.

It’s common for patients on chemotherapy to find that marijuana suppresses their nausea and improves their appetite. Some patients with severe pain use cannabis as an alternative to opioids and their undesirable side effects.

As with most things involving medical marijuana, good data is hard to come by. But a January study in the journal Gerontologist found that cannabis “may be an effective substitute for prescription opioids and other misused medications;” as well as “an alternative for the undertreatment of pain at the end of life.”

PEÑA’S WORK FOR PATIENTS

In some hospice facilities, patients “have to either hide it or go home,” Peña said, especially those organizations scared of losing federal funds. “I’ve talked to other patients where the nurses are OK with it.” Some nurses, she said, will even administer it.

From Piña – Because of our mom’s journey and the vast knowledge we’ve gained during her healing journey, we decided we wanted to change this, and we decided to establish Myriam’s Hope, as we just couldn’t sit back and watch as others are suffering knowing there is something so pure and natural that can help for so many diseases. We would like to welcome you to an alternative treatment therapy and provide you with a safe haven to access this amazing medicinal extract we simply call Cannabis Oil. Please join us and help us help you.

With more than half the states endorsing marijuana’s value as a medicine for patients with terminal illnesses, Peña said it “has to be a closed-minded doctor who doesn’t want to see this is helpful for patients.”

 

 

https://medicalmarijuana411.com/daughter-starts-medical-marijuana-collective-mothers-passing/?utm_source=newsletter093017&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

4 Things to Know About Vitamin D and Multiple Sclerosis

Vitamin D is often talked about as an important vitamin that helps the body stay fit and strong, but it could also help in the fight against multiple sclerosis (MS). While there still needs to be more research into the beneficial effects of vitamin D, there are some things to know about its relationship with MS.

https://vitaminadperlasclerosimultipla.wordpress.com/tag/protocollo-coimbra/

It can slow the progression of multiple sclerosis.

There is some evidence that suggests people with multiple sclerosis who have higher levels of vitamin D in their bodies are likely to suffer less severe symptoms. According to Web MD, a study noted the symptoms of a group of people with MS and then found that five years later, those with higher levels of vitamin D experienced fewer problems. While this shows promise, more research needs to be conducted into whether vitamin D can actually slow down the progression of MS.

MORE: Three tips for newly diagnosed multiple sclerosis patients.

It may prevent multiple sclerosis.

Other studies have found that vitamin D may be helpful in the prevention of the disease. Researchers discovered that children who spent a lot of time outside in the sunshine were less likely to develop the disease later in life.

This is also backed up by the fact that the further away from the equator you live, the higher your risk of developing MS becomes, as the amount of sunshine diminishes.

To date, no-one is really sure what role vitamin D plays in protecting people against MS. Many think that vitamin D enhances the immune system, making it less likely for a person to develop an autoimmune disease like MS.

How much vitamin D do you need?

A simple blood test can determine your levels of vitamin D. The National Multiple Sclerosis Society suggests that people living with the disease get between 200 and 600 IUs (international units) a day.

How can you improve your vitamin D intake?

You can either take a supplement (if recommended by your healthcare team), spend 15 minutes each day in the sun, or eat more food containing vitamin D such as oily fish, beef liver, cheese, eggs and foods fortified
with vitamin D such as cereals, milk and orange juice.

 

MORE: How our bodies convert sunlight into vitamin D.

 

 

https://multiplesclerosisnewstoday.com/2017/09/20/things-to-know-vitamin-d-multiple-sclerosis/?utm_source=Multiple+Sclerosis&utm_campaign=664d0eb059-RSS_FRIDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-664d0eb059-71362689

DR. MARK WARE DISCUSSES CANNABIS AS MEDICINE

 

Transcript: I first became familiar with about 10 years ago, when I beginning to explore the area of medical cannabis research, writing up grants, doing interviews with patients and beginning to explore this. I became aware that there was this conference being held at I think at the University of Iowa the first one, I didn’t have any funding to get there. So I called them up and I said, is there a video link up, is there some way I can dial into this to watch it from Montreal where I was based. I was able to speak to McGill, and they lent me a room, a video screen and a projector. I watched the whole thing sitting a room, there were three or four of us sitting this room and watched the whole congress. I was amazed in the level of science, and the stories, the patient involvement. What I really liked was the patient involvement.

Even today when I gave my talk, I ask the room how many people were patients in the room, and over half the room was patients. Most of the talks that I do, are working with the physicians and scientists. Its really rewarding to speak to patients, meet them afterward and interact and see the level of interest they have in getting that knowledge.

I respect the work Al and Mary are doing to keep that patient presence alive through all of this. I think its motivated by the fact that the very first patient, who told me that he used cannabis for medical purposes, looked me in the eye and told me that. It struck me, and I thought wow, OK, and I believed him. I as I said earlier its still something where I believe strongly, that we have to listen to that voice. I think for a long time the medical profession has preached, this is what we think is right for you. Here we have for various reasons, political, legal, whatever, a position where patients have come forward saying, this is working for me. Hearing those voices, hearing that, knowing there is a bit of a barrier to the science, but knowing that it is overcome able, we can do it.

That motivates me. And knowing at the end of the day, a patient who has struggled with their physician, struggled with their family members, because they perceive this is drug abuse, or a substance they are worried about. If they feel somehow legitimized by the fact there are doctors and scientists who are studying this, and feel that it is a potentially useful therapy. If they feel reassured, if the family says OK, well maybe its OK, and then I think we have done a good service.

For more on the video series, here are links to part one and two:

Dr. Mark Ware Discusses Cannabis As Medicine Part One
Dr. Mark Ware Discusses Cannabis As Medicine Part Two

Dr. Mark A. Ware MBBS MRCP (UK) is a family physician and Associate Professor in Family Medicine and Anesthesia at McGill University. He is the Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre, co-Director of the Quebec Pain Research Network, and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids. He practices pain medicine at the Montreal General Hospital.

In the past 10 years Dr. Ware has given numerous lectures across Canada on pain to health care practitioners and the public. He teaches pain medicine and integrative medicine to medical students at McGill and was recently appointed as a McGill Teaching Scholar to coordinate pain education in the medical school curriculum.

Dr. Ware’’s primary research interests are in evaluating the safety and effectiveness of medicines derived from cannabis (cannabinoids), population-based studies of the impact of pain on the population, and complementary therapies in pain and symptom management.

 

 

https://medicalmarijuana411.com/dr-mark-ware-discusses-cannabis-medicine/?utm_source=newsletter091417&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

OSTEOPOROSIS

Raphael Mechoulam (Hebrew: רפאל משולם‎) (born 1930) is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.

Transcript: These two receptors that are specific to cannabinoids. But cannabinoids also, some of them bind to other receptors. There is one-called 133 I think, GPR133, there is another one, which is GPR18. I may be mistaken on the numbers, but I think GPR18, GPR133 and so on.

They are not specific for the cannabinoids so there is a lot of discussion between the pharmacologists should we call them cannabinoid receptors. The decision at the moment is lets wait and sees. At the moment we have only two that have been approved as cannabinoid receptors. All the others with a question mark.

Two receptors have evolved for certain specific conditions, feeding for example, appetite, feeding, and things of that sort. But some of the other actions most definitely go through other systems. We do not know enough and where they, a lot of compounds, endogenous compounds, which do a huge number of things. For example tomorrow, I will be talking about a compound which is chemically is very closely related to Anandamide, yet, it does not bind to the receptor, but it has quite a few other effects. Its a vaso-relaxant for example, thats important, because when one gets a head injury, many things happening at the same time. One of them is vaso-constriction, this compound is a vaso-relaxant and is produced by the brain, and chemically its very close to Anandamide but it doesn’t bind to the cannabinoid receptor.

There are other things for example, in the bone we have endogenous compounds like R2AG, which acts and lowers the damage of Osteoporosis. It increases osteoblats, and reduces osteoplasts. (which receptor does this go through?). CB2, well mostly CB2, it acts on CB1 as well, but not directly, indirectly. But we have an additional compound. For example in the bone, we are speaking about bones, there is a compound, Oliel-Seerin which is chemically related to Anandamide but it does not bind to the receptor, and yet it lowers the damage of osteoporosis.

 

 

https://medicalmarijuana411.com/dr-raphael-mechoulam_part-six-mov/?utm_source=newsletter091417&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

https://roscia2010.wordpress.com/2016/06/01/cannabis-for-osteoporosis-prevention/